脂联素与非酒精性脂肪肝病  

Role of adiponectin in nonalcoholic fatty liver disease

作　　者：石胜利 聂玉强[2] 

机构地区：[1]广山市小榄人民医院消化科,广东省中山市528415 [2]广州医学院附属市一人民医院消化科,广东省广州市510180

出　　处：《世界华人消化杂志》2007年第3期272-275,共4页World Chinese Journal of Digestology

摘　　要：脂联素(adiponectin,ADP)作为一种新发现的脂肪激素,主要是由脂肪细胞分泌的,在肥胖者、糖尿病及非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)患者中血清ADP水平低于正常.ADP有胰岛素增敏作用,与胰岛素抵抗相关;能够使肝脏肿瘤坏死因子(tumor necrosis factor-alpha,TNF-α)分泌下降,减少肝中脂肪堆积和炎症介质作用,对ADP的研究将为探讨NAFLD的发病机制及治疗方案提供新的线索.Adiponectin, discovered recently, is kind of adipose hormone that is secreted by adipose cells, and its serum level is lower in patients with adiposity, diabetes mellitus, and nonalcoholic fatty liver disease （NAFLD） than that in healthy individuals. Plasma adiponectin is in close correlation with the sensitivity of insulin and play an important role in insulin resistance. Meanwhile, adiponectin can inhibit the production of liver tumor necrosis factor-alpha and reduce the lipid accumulation and inflammatory reaction during liver injury. Therefore, we assessed the relationship between adiponectin and NAFLD in order to explore the role of adiponectin in the pathogenesis and treatment of NADLD.

关 键 词：脂联素 脂联素受体 非酒精性脂肪肝 发病机制 

分 类 号：R575.5[医药卫生—消化系统]